A Message from VGXI Regarding the Coronavirus (COVID-19) Outbreak and VGXI Actions LAST UPDATED July 24, 2020 To our Valued Clients and Business Partners, VGXI recognizes your concerns regarding the potential impact of the coronavirus outbreak on our products and services. VGXI is actively monitoring the situation and will continue to provide… Read More »
Meet with representatives from VGXI at the 2nd Annual AAV Gene Therapy Symposium on 10 December, 2018. We would welcome an opportunity to introduce ourselves and share information on VGXI’s customized plasmid DNA manufacturing solutions to support your AAV production needs. Contact Us today to request a meeting. 2018 AAV Gene Therapy Symposium 10… Read More »
Will you be attending the Annual Congress of the International Society for Vaccines (ISV) in October, 2018? Meet with representatives from VGXI at Booth # 4 and learn more about our products and services! Or contact Us today to request a meeting time. ISV 2018 Congress 28-30 October, 2018 Marriot Marquis Hotel Atlanta,… Read More »
Will you be attending the 26th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) in October, 2018? Representatives from VGXI will be attending and we would welcome an opportunity to share more about our plasmid DNA products and services! Contact Us today to make arrangements. ESGCT 26th Annual Congress 16-19 October,… Read More »
Texas based CMO VGXI Announces Licensing Agreement with the Houston Methodist Research Institute for Production of RNA Therapeutics. The Woodlands, TX – September 17, 2018: VGXI, an industry leading plasmid DNA contract manufacturer, announced today that they have entered into an exclusive license with the Houston Methodist Research Institute to produce clinical… Read More »
GeneOne Announces that its Subsidiary, Industry Leading Plasmid DNA CMO VGXI, has Entered into an Exclusive License to Produce RNA Biotherapeutics. Seoul, Korea – September 17, 2018: GeneOne Life Science announced today that its subsidiary VGXI, an industry leading plasmid DNA contract manufacturer, has entered into an exclusive license with the Houston… Read More »
Will you be attending the BIO International Convention in June, 2018? Meet with representatives from VGXI at Booth # 721 and learn more about our products and services! We also welcome requests for partnering meetings during the conference. Contact Us today to make arrangements. BIO International Convention 04 – 07 June, 2018 Boston Covention and Exhibition… Read More »
VGXI, a Texas-based cGMP plasmid CMO, will provide manufacturing support under client’s $56M CEPI award for the development of Lassa and MERS vaccines. The Woodlands, TX – April 30, 2018 – VGXI announced today they will collaborate with one of their clients on a recent $56,000,000 award from the Coalition for Epidemic… Read More »
GMP plasmid CMO VGXI appoints Dorothy Peterson as Chief Operating Officer, overseeing all aspects of the Texas-based production facility. The Woodlands, TX – April 25, 2018 – VGXI is pleased to announce that Vice President of Operations Dorothy Peterson has been appointed Chief Operating Officer. Peterson joined VGXI in 2007 as the… Read More »
Will you be attending the ASGCT 21st Annual Meeting in May, 2018? Meet with representatives from VGXI at Booth # 105 and learn more about our products and services! We also welcome requests for partnering meetings during the conference. Contact Us today to make arrangements. ASGCT’s 21st Annual Meeting 16-19 May, 2018 Hilton Chicago
Will you be attending the World Vaccine Congress in April 2018? Meet with representatives from VGXI at Booth # 212 and learn more about our products and services! We also welcome requests for partnering meetings during the conference. Contact Us today to make arrangements. Still need to register? Join VGXI at WVC 2018 using the discount code… Read More »
As a leading GMP manufacturer of high quality plasmid DNA, VGXI, Inc. has been recognized in the final shortlist of companies for the category of “Best Contract Manufacturing Organization (CMO)” for the 2018 Vaccine Industry Excellence Awards. Click here to view the full list of finalists for the ViE Awards Will you be attending the World… Read More »
Texas based plasmid CMO VGXI breaks ground on facility expansion and new flex-scale GMP production plants. The Woodlands, TX – February 22, 2018 – VGXI announced today they have broken ground on a 5,000 square foot expansion of their Texas based manufacturing facility. Once complete, the project will increase the company’s footprint… Read More »
Sign Up
For more information